ClinicalTrials.gg
CompletedNCT07210684DHBUpdated Nov 13, 2026

Effects of Dihydroberberine (DHB) on GLP-1, Glycemic Control, Appetite, and Mood in Adults With Pre-Diabetes

An interventional study of Placebo 400 mg and Dihydroberberine(DHB)400 mg in Prediabetes, sponsored by Nanjing Nutrabuilding Bio-tech Co., Ltd.. Completed at 1 site in United States. Open to participants aged 35 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Nanjing Nutrabuilding Bio-tech Co., Ltd. · Not applicable, Interventional, and Other

How we know

Updated Nov 13, 2026Now CompletedPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
35 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 390 studies in Prediabetic State with a site in United States — 83 open to participants now, 107 under way, 2 of them phase 3. Prediabetic State · United States.

Enrollment
178th of 362
54 · median 54
Started
2025
with 27 others
No phase
288 of 390
58 open now
Registered
352nd of 390
by date

Among the 390 studies in Prediabetic State with a site in United States, this one is the 178th largest by enrollment of the 362 interventional ones that give a count, is one of 28 that started in 2025, is one of 288 with no phase, and was the 352nd registered.

Prediabetic State

919 studies on the registry are indexed under Prediabetic State; 231 are open to participants now.

Browse Prediabetic State studies →

Open to participants now

83 of the 390 studies in Prediabetic State with a site in United States are open now. Recruiting first, the newest first:

78 more — sign in →

All 83 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 144 Prediabetic State studies recruiting now, 51 (35%) set no upper age limit and 83 (58%) stop at 75 or younger; 12 take children under 18; 54 take healthy volunteers.

This study: 35 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 390 studies in Prediabetic State with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if Dihydroberberine (DHB) supplementation affects adults with pre-diabetes.

The main questions it aims to answer are:

Does DHB supplementation increase the concentration of GLP-1 in the blood? Does DHB supplementation affect appetite, mood, and energy levels? Does DHB supplementation affect body weight, blood sugar control and insulin? Researchers will compare DHB supplementation to a placebo (a look-alike substance that contains no drug) to see if DHB has any effect.

Participants will:

Take DHB or a placebo every day for 6 weeks. Participate in tests to measure GLP-1 levels, blood glucose, insulin and other markers.

Have their continuous blood sugar profiles (with CGMs) monitored to see how much time their blood sugar spends in a healthy range.

Rate their appetite, mood, and energy levels using a visual analog scale.

03

Conditions studied

  • Prediabetes

Browse trials for

Keywords

  • GlucoVantage®
  • DHB
  • Dihydroberberine
  • GLP-1
  • Glucagon-Like Peptide-1
  • Blood glucose
  • Appetite and Mood/Energy
04

Who can participate

Ages eligible
35 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1.35 - 65 years of age (inclusive). 2. 25.0 - 35.0 kg/m2 (inclusive). 3. 5.7% - 6.4% (39 - 47 mmol/mol, inclusive) measured at visit 1. 4.Participant has a score of 7 - 10 on the Vein Access Scale Assessment at visit 1.

5.Non-user or former user (daily use; cessation ≥12 months) of tobacco or nicotine products (e.g., cigarette smoking, vaping, chewing tobacco) within 12 months of visit 1, and has no plans to begin use during the study period.

6.Non-habitual users (i.e., daily or almost daily) of marijuana or hemp products, including CBD/THC products, and willing to abstain from use throughout the study period (topical creams/lotions are allowed).

7.Willing to wear a CGM sensor throughout study period and willing to adhere to instructions/ restrictions associated with the proper use and care of the CGM.

8.Willing to use personal smart phone with operating system capable of downloading and operating the Cronometer and Dexcom CGM apps for diet records and blood glucose, respectively.

9.Willing to adhere to all study procedures, including lifestyle considerations, and sign forms providing to participate in the study and authorization to release relevant protected health information to the Clinical Investigator.

Exclusion criteria

Exclusion Criteria:

  1. Extreme Diets: Extreme dietary habits (e.g., ketogenic, vegan/vegetarian) at investigator's discretion.
  2. Intense Exercise: Moderate-to-intense physical training (≥5 hours/week).
  3. Weight Instability/Program: Recent weight changes (>4.5 kg≤90 d) or current/planned weight change program.
  4. Abnormal Labs: Abnormal lab test results of clinical significance at Visit 1 (one re-test allowed).
  5. Uncontrolled Chronic Illness: Uncontrolled or pulmonary, cardiac, hepatic, renal, endocrine (T1D/T2D excluded), hematologic, immunologic, neurologic, psychiatric, or biliary disorders.
  6. Clinically Important GI: Clinically important GI condition interfering with study product (e.g., IBD, celiac, weight loss surgery history).
  7. Uncontrolled HTN: Uncontrolled hypertension (SBP≥160 mmHg and/or DBP≥100 mmHg).
  8. Cancer History: History or presence of cancer in the prior 2 years (except non-melanoma skin cancer).
  9. Active Infection: Signs/symptoms of active infection ≤5 d of Visit 1.
  10. Anti-Hyperglycemics: Recent use (≤6 mo) of any prescription anti-hyperglycemic medication.
  11. Other Supplements: Use of dietary supplements (other than approved multivitamin) ≤14 d of Visit 1.
  12. Alcohol/Substance Abuse: History (≤12 months) of alcohol (>14 drinks/week) or substance abuse.
  13. Antibiotics: Antibiotic use ≤90 d of Visit 1.
  14. Regular NSAIDs: Regular use (≥3 days/week≤30 d) of anti-inflammatory medications.
  15. Use: Recent use (≤30 d) of oral/injectable steroids, or high-dose topical/inhaled steroids.
  16. Unregistered Drug: Exposure to any non-registered drug product ≤30 d prior to Visit 1
  17. Medication Instability: Unstable dose (≤90 d) of any other prescription medications (PRN excluded).
  18. Psychiatric Hospitalization: Major affective/psychiatric disorder requiring hospitalization ≤12 months prior to Visit 1.
  19. Recent Trauma/Surgery: Major trauma or any surgical event ≤30 d of Visit 1.
  20. Recent GI Prep: Endoscopy or colonoscopy preparation ≤90 d prior to Visit 1.
  21. Planned Surgery: Scheduled or planning elective surgical procedures during the study.
  22. Female Status: Pregnancy, lactation, planning pregnancy, or unwillingness to use approved .
  23. Allergies: Known sensitivity or allergy to any study products or foods.
  24. Investigator Discretion: Any condition that interferes with compliance, confounds results, or presents undue risk.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Dietary Supplement: Placebo 400 mg

  • Experimental
    Dihydroberberine(DHB)

    Dietary Supplement: Dihydroberberine(DHB)400 mg

Interventions

  • Dietary supplementPlacebo 400 mg

    Participants will receive 4 placebo capsules daily for 6 weeks. Each capsule contains 100 mg of microcrystalline cellulose, which serves as a inactive control substance.

  • Dietary supplementDihydroberberine(DHB)400 mg

    Participants will receive 4 capsules of DHB (Dihydroberberine) 100 mg each, orally, once daily for 6 weeks. The total daily dose is 400 mg of DHB.

06

What researchers measure

Primary outcomes

  1. Change in Postprandial Total GLP-1 Cmax After Single Dose of DHB

    Change in postprandial total glucagon-like peptide-1 (GLP-1) maximum concentration (Cmax) following a single dose of 200 mg DHB compared to placebo, measured at visit 3, day 0.

    Time frame: Visit 3, Day 0 (after single dose administration)

  2. Change in GLP-1 Cmax From Baseline to End of Study After 6 Weeks of DHB

    Change in postprandial total GLP-1 maximum concentration (Cmax) from baseline to end of study after 6 weeks of daily supplementation with 400 mg DHB vs. placebo.

    Time frame: Baseline to End of Study , approximately Week 6

Secondary outcomes

  1. Change in Postprandial GLP-1 AUC (piAUC0-120min) After Single Dose of DHB

    Positive incremental AUC (piAUC0-120min) as calculated by the linear trapezoid method where the fasting levels will be subtracted from post-product consumption time points and levels lower than baseline will be truncated at 0

    Time frame: 0-120 minutes post-meal at Baseline and Acute Visit 3, Day 0

  2. Change in Time to Maximum Concentration (Tmax) of Postprandial GLP-1 After Single Dose of DHB

    Time frame: 0-120 minutes post-meal at Baseline and Acute Visit 3, Day 0

  3. Change in Fasting Total GLP-1 Levels from Baseline (day -7) to the Acute Visit 3 (day 0)

    Time frame: From Baseline (Visit 2, Day -7) to Acute Visit (Visit 3, Day 0)

  4. Postprandial Glucose and insulin Responses After Single Dose

    Postprandial responses of plasma glucose and insulin during MTT at visit 3, day 0 after single-dose DHB (200 mg) vs. placebo, including: 1. maximum concentration (Cmax); 2. time to peak (Tmax); 3. positive incremental AUC (piAUC0-120min); 4. fasting levels.

    Time frame: 0-120 minutes post-meal at Visit 3, Day 0

  5. Change in Subjective Appetite Perceptions After Single Dose of DHB

    Appetite VAS ratings quantified by the following metrics: (1)0-120 min net incremental AUC (niAUC0-120min) as calculated by the linear trapezoid method where the baseline values (measured at t = -45 min) will be subtracted from post product consumption time points; 1. Composite appetite score (\[desire to eat + hunger + (100 - fullness) + prospective consumption\]/4); 2. Individual VAS ratings: Hunger; Desire to eat; Fullness; Prospective food consumption ; (2)Positive maximum response (i.e., change from the fasted value t = -45 min) appetite for composite and individual VAS ratings; (3)Fasting (t = -45 min) appetite for composite and individual VAS ratings;

    Time frame: 0-120 minutes post-meal at Visit 3, Day 0

  6. Time In/Out of Range of 24-Hour Continuous Glucose Monitoring (CGM) Glycemic Health Endpoints

    1. Time In Range (TIR) and percentage of TIR where the target range is 70 - 180 mg/dL; 2. Time In Tight Range (TITR) and percentage of TITR where the tight target range is 70 - 140 mg/dL ; 3. Time above range and the percentage of readings \>180 mg/dL ; 4. Time below range and the percentage of readings \< 70 mg/dL.

    Time frame: 24 hours following product intake (Visit 3, Day 0)

  7. Mean Glucose and Variability of 24-Hour Continuous Glucose Monitoring (CGM) Glycemic Health Endpoints

    1. Change in Mean 24-Hour Glucose: Mean glucose averaged over the 24 collection period; 2. Glycemic Variability (Coefficient of Variation (CV) ): Glycemic variability defined by the Standard Deviation (SD) and CV over the 24 h collection period.

    Time frame: 24 hours following product intake (Visit 3, Day 0)

  8. Change in Postprandial GLP-1 (piAUC0-120min) After 6 Weeks of Supplementation

    Change in positive incremental area under the curve (piAUC0-120min) for plasma total GLP-1 during the Meal Tolerance Test (MTT) from baseline (Visit 2, Day -7) to end of study (Visit 4, Day 42) following 6 weeks of daily DHB supplementation (400 mg/day) vs. placebo, calculated using the linear trapezoidal method.

    Time frame: Baseline (Visit 2, Day -7) to End of Study (Visit 4, Day 42), approximately Week 6

  9. Change in Postprandial Total GLP-1 Time to Maximum Concentration (Tmax) from Baseline to Week 6

    Change in the Time to Tmax of plasma total GLP-1 during the MTT from baseline (Visit 2, Day -7) to end of study (Visit 4, Day 42) following 6 weeks of daily DHB supplementation (400 mg/day) vs. placebo

    Time frame: Baseline (Visit 2, Day -7) to End of Study (Visit 4, Day 42), approximately Week 6

  10. Change in Fasting Plasma Total GLP-1 Levels from Baseline to Week 6

    Change in fasting plasma total GLP-1 levels from baseline (Visit 2, Day -7) to end of study (Visit 4, Day 42) following 6 weeks of daily DHB supplementation (400 mg/day) vs. placebo.

    Time frame: Baseline (Visit 2, Day -7) to End of Study (Visit 4, Day 42), approximately Week 6

  11. Change in Postprandial Plasma Glucose Maximum Concentration (Cmax) from Baseline After 6 Weeks of Supplementation

    Change in plasma glucose dynamics from baseline (Visit 2, day 0) to end of study (Visit 4, Day 42) following 6 weeks of daily DHB supplementation (400 mg/day) vs. placebo, assessed during the MTT.

    Time frame: Baseline (Visit 2, day 0) to End of Study (Visit 4, Day 42), approximately Week 6

  12. Change in Postprandial Plasma Glucose Time to Peak Concentration (Tmax) from Baseline After 6 Weeks of Supplementation

    Change in plasma glucose dynamics from baseline (Visit 2, day 0) to end of study (Visit 4, Day 42) following 6 weeks of daily DHB supplementation (400 mg/day) vs. placebo, assessed during the MTT.

    Time frame: Baseline (Visit 2, day 0) to End of Study (Visit 4, Day 42), approximately Week 6

  13. Change in Postprandial Plasma Glucose Positive Incremental Area Under the Curve (piAUC0-120min) from Baseline After 6 Weeks of Supplementation

    Change in plasma glucose dynamics from baseline (Visit 2, day 0) to end of study (Visit 4, Day 42) following 6 weeks of daily DHB supplementation (400 mg/day) vs. placebo, assessed during the MTT.

    Time frame: Baseline (Visit 2, day 0) to End of Study (Visit 4, Day 42), approximately Week 6

  14. Change in Fasting Plasma Glucose Levels from Baseline to Week 6

    Change in plasma glucose dynamics from baseline (Visit 2, day 0) to end of study (Visit 4, Day 42) following 6 weeks of daily DHB supplementation (400 mg/day) vs. placebo, assessed during the MTT.

    Time frame: Baseline (Visit 2, day 0) to End of Study (Visit 4, Day 42), approximately Week 6

  15. Change in Postprandial Plasma Insulin Time to Peak Concentration (Tmax) from Baseline After 6 Weeks of Supplementation

    Change in plasma insulin dynamics from baseline (Visit 2, day 0) to end of study (Visit 4, Day 42) following 6 weeks of daily DHB supplementation (400 mg/day) vs. placebo, assessed during the MTT.

    Time frame: Baseline (Visit 2, day 0) to End of Study (Visit 4, Day 42), approximately Week 6

  16. Change in Postprandial Plasma Insulin Positive Incremental Area Under the Curve (piAUC0-120min) from Baseline After 6 Weeks of Supplementation

    Change in plasma insulin dynamics from baseline (Visit 2, day 0) to end of study (Visit 4, Day 42) following 6 weeks of daily DHB supplementation (400 mg/day) vs. placebo, assessed during the MTT.

    Time frame: Baseline (Visit 2, day 0) to End of Study (Visit 4, Day 42), approximately Week 6

  17. Change in Fasting Plasma Insulin Levels from Baseline to Week 6

    Change in plasma insulin dynamics from baseline (Visit 2, day 0) to end of study (Visit 4, Day 42) following 6 weeks of daily DHB supplementation (400 mg/day) vs. placebo, assessed during the MTT.

    Time frame: Baseline (Visit 2, day 0) to End of Study (Visit 4, Day 42), approximately Week 6

  18. Change in Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) After 6 Weeks

    Change in insulin resistance index from baseline (Visit 2) to end of study (Visit 4) following 6 weeks of daily DHB supplementation (400 mg/day) vs. placebo. HOMA-IR is calculated as \[fasting insulin (mU/L) × fasting glucose (mg/dL)\] / 405.

    Time frame: Baseline (Visit 2) to End of Study (Visit 4), approximately Week 6

  19. Change in Postprandial Insulin Maximum Concentration (Cmax) from Baseline to Week 6

    Change in plasma insulin dynamics from baseline (Visit 2, day 0) to end of study (Visit 4, Day 42) following 6 weeks of daily DHB supplementation (400 mg/day) vs. placebo, assessed during the MTT.

    Time frame: Baseline (Visit 2, day 0) to End of Study (Visit 4, Day 42), approximately Week 6

  20. Change in Appetite Perceptions for composite VAS ratings After 6 Weeks of Supplementation

    Change in appetite VAS ratings from baseline (Visit 2) to the end of study (Visit 4) : 1. niAUC0-120min appetite for composite VAS ratings 2. Positive maximum response appetite for composite VAS ratings 3. Fasting appetite for composite VAS ratings The Appetite Visual Analog Scale (VAS) is used to assess subjective feelings of appetite. This VAS contains four questions related to appetite (hunger, desire to eat, fullness, and prospective food consumption). The scores are interpreted as follows: composite appetite where lower scores indicate less appetite; hunger where lower scores indicate less hunger; desire to eat where lower scores indicate less desire to eat; fullness where high scores indicate more fullness; prospective food consumption where lower scores indicate less prospective food consumption.

    Time frame: Baseline (Visit 2, Day -7) to End of Study (Visit 4, Day 42), approximately Week 6

  21. Change in Appetite Perceptions for individual VAS ratings After 6 Weeks of Supplementation

    Change in appetite VAS ratings from baseline (Visit 2) to the end of study (Visit 4) : 1. niAUC0-120min appetite for individual VAS ratings 2. Positive maximum response appetite for individual VAS ratings 3. Fasting appetite for individual VAS ratings The Appetite Visual Analog Scale (VAS) is used to assess subjective feelings of appetite. The scale consists of a continuous line that ranges from 0 to 100 mm. The four specific scale items assessed during the MTT are: 1. How hungry do you feel? (Anchor: 0 = Not hungry at all; 100 = As hungry as I have ever felt) 2. How strong is your desire to eat? (Anchor: 0 = Not strong at all; 100 = As strong as I have ever felt) 3. How full do you feel? (Anchor: 0 = Not full at all; 100 = As full as I have ever felt) 4. How much food do you think you can eat? (Anchor: 0 = Nothing at all; 100 = A large amount)

    Time frame: Baseline (Visit 2, day 0) to End of Study (Visit 4, Day 42), approximately Week 6

  22. Time In/Out of Range of 7-Day Continuous Glucose Monitoring (CGM) Parameters After 6 Weeks

    1. Time In Range (TIR) and percentage of TIR where the target range is 70 - 180 mg/dL; 2. Time In Tight Range (TITR) and percentage of TITR where the tight target range is 70 - 140 mg/dL; 3. Time above range and the percentage of readings \>180 mg/dL; 4. Time below range and the percentage of readings \<70 mg/dL.

    Time frame: 7-day monitoring period before Visit 2 (Day -7) and Visit 4 (Day 42)

  23. Mean Glucose Averaged and Variability of Over 7 Days from Baseline to Week 6

    1. Mean glucose averaged over the 7-day collection period; 2. Glycemic variability defined by the SD and CV over the 7-day collection period.

    Time frame: 7-day monitoring period before Visit 2 (Day -7) and Visit 4 (Day 42)

Other outcomes

  1. Change in Body Weight After 6 Weeks of DHB Supplementation

    Change in body weight from day 0 to day 42 following 6 weeks of daily DHB supplementation (400 mg/day) vs. placebo.

    Time frame: Baseline to End of Study (Day 42), approximately Week 6

  2. Change in Perceived Energy After 6 Weeks of DHB Supplementation

    Change in energy VAS rating from day 0 to day 42 following 6 weeks of daily DHB supplementation (400 mg/day) vs. placebo. The title of scales is Mental and Physical State Energy and Fatigue State Scales (EFSS). The Energy VAS will be the 6-item Mental and Physical State Energy and Fatigue Scale where participants rate their current subjective feelings of physical and mental energy and fatigue. Energy is a composite score of answers regarding energy, vigor, and pep. Fatigue is a composite score regarding fatigue, exhaustion, and worn-out. Respective individual scores are summed to composite scores ranging from 0 to 300.

    Time frame: Baseline to End of Study (Day 42), approximately Week 6

  3. Change in Mood Status After 6 Weeks of DHB Supplementation

    Change in Profile of Mood States (POMS) scores from day 0 to day 42 following 6 weeks of daily DHB supplementation (400 mg/day) vs. placebo. The title of scale is Profile of Mood States (POMS). The POMS-2 is a self-report assessment of mood. The POMS-2 can be evaluated for a composite total mood disturbance score and 6 component scores of anger-hostility, confusion-bewilderment, depression-dejection, fatigue-inertia, tension-anxiety, and vigor-activity.

    Time frame: Baseline to End of Study (Day 42), approximately Week 6

07

Study locations

1 site
08

References and documents

Publications

  • Moon JM, Ratliff KM, Hagele AM, Stecker RA, Mumford PW, Kerksick CM. Absorption Kinetics of Berberine and Dihydroberberine and Their Impact on Glycemia: A Randomized, Controlled, Crossover Pilot Trial. Nutrients. 2021 Dec 28;14(1):124. doi: 10.3390/nu14010124. PubMed 35010998 ↗
  • Panigrahi A, Mohanty S. Efficacy and safety of HIMABERB(R) Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial. BMC Endocr Disord. 2023 Sep 7;23(1):190. doi: 10.1186/s12902-023-01442-y. PubMed 37679692 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2025 to primary completion in Sep 2026, 13 months.

Of 379 non-industry interventional studies with no phase under Prediabetic State, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 38. This study's 13 months is below that.

Counting every sponsor, half of 425 studies reached it within 23 months; a quarter within 11 and three quarters within 37.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Jan 2026 → Sep 2026 and completion Mar 2026 → Sep 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 18, 2025
First posted
Oct 7, 2025
StartActual
Aug 6, 2025
Primary completionActual
Sep 30, 2026was Jan 2026
CompletionActual
Sep 30, 2026was Mar 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Completed
changed Nov 13, 2026
Primary completion
Jan 15, 2026→Sep 30, 2026 (actual)
Nov 13, 2026
Study completion
Mar 15, 2026→Sep 30, 2026 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Recruiting→Completed
    Primary completion Jan 15, 2026→Sep 30, 2026 (now actual)
    Study completion Mar 15, 2026→Sep 30, 2026 (now actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07210684
Lead sponsor
Nanjing Nutrabuilding Bio-tech Co., Ltd.
Collaborators
Biofortis, Merieux NutriSciences
Responsible party
Sponsor
First posted
Oct 7, 2025
Start date
Aug 6, 2025
Primary completion
Sep 30, 2026
Completion
Sep 30, 2026
Last update
Nov 13, 2026

Study contacts

Elizabeth Antoo, MD
principal investigator · Biofortis, Inc. Merieux NutriSciences

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion